Forge Biologics snags $120m Series B

Forge Biologics, a gene therapy-focused contract development and manufacturing organization, has secured $120 million in Series B financing.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this